Ziding Feng1, Jorge A Marrero2, Saira Khaderi3,4, Amit G Singal2, Fasiha Kanwal4, Nicole Loo5, Laura Beretta6, Jing Ning1, Hashem B El-Serag4. 1. Department of Biostatistics, UT MD Anderson Cancer Center, Houston, Texas, USA. 2. Division of Digestive and Liver Diseases, Department of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA. 3. Division of Abdominal Transplantation, Baylor College of Medicine, Houston, Texas, USA. 4. Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine and Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA. 5. Department of Medicine, Texas Liver Institute, San Antonio, Texas, USA. 6. Department of Molecular and Cellular Oncology, UT MD Anderson Cancer Center, Houston, Texas, USA.
Abstract
OBJECTIVES: The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis. METHODS: Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit. RESULTS: The primary outcome was the development of HCC. Biomarkers were tested in banked blood samples using prospective specimen collection, retrospective blinded evaluation design. CONCLUSIONS: We describe study design, eligibility criteria, recruitment, study cores, and sample size and analysis considerations.
OBJECTIVES: The Texas Hepatocellular Carcinoma Consortium cohort study investigates risk factors of hepatocellular carcinoma (HCC) and biomarkers for early HCC detection in patients with liver cirrhosis. METHODS: Adult patients with liver cirrhosis are enrolled at 5 clinical centers from 3 cities in Texas, with a target of 5,000 patients. Clinical history, risk factor questionnaires, liver imaging, laboratory data, and blood samples were collected at enrollment and at each 6-month follow-up visit. RESULTS: The primary outcome was the development of HCC. Biomarkers were tested in banked blood samples using prospective specimen collection, retrospective blinded evaluation design. CONCLUSIONS: We describe study design, eligibility criteria, recruitment, study cores, and sample size and analysis considerations.
Authors: Fasiha Kanwal; Saira Khaderi; Amit G Singal; Jorge A Marrero; Nicole Loo; Sumeet K Asrani; Christopher I Amos; Aaron P Thrift; Xiangjun Gu; Michelle Luster; Abeer Al-Sarraj; Jing Ning; Hashem B El-Serag Journal: Hepatology Date: 2022-03-01 Impact factor: 17.298
Authors: Kali Zhou; Trevor A Pickering; Christina S Gainey; Myles Cockburn; Mariana C Stern; Lihua Liu; Jennifer B Unger; Anthony B El-Khoueiry; Norah A Terrault Journal: JNCI Cancer Spectr Date: 2020-11-02
Authors: Neehar D Parikh; Anand S Mehta; Amit G Singal; Timothy Block; Jorge A Marrero; Anna S Lok Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-04-01 Impact factor: 4.254
Authors: Ruben Hernaez; Jennifer R Kramer; Aisha Khan; Jessica Phillips; Katharine McCallister; Kassie Chaffin; Adriana Portela Hernandez; Hannah Fullington; Cynthia Ortiz; James-Michael Blackwell; Adam Loewen; Yan Liu; Jasmin A Tiro; Simon C Lee; Amit G Singal Journal: Clin Gastroenterol Hepatol Date: 2020-08-21 Impact factor: 11.382
Authors: Nabihah Tayob; Douglas A Corley; Israel Christie; Lucy Almers; Ahmed K Rahal; Peter Richardson; Donna L White; Jessica Davila; Fasiha Kanwal; Hashem B El-Serag Journal: Clin Gastroenterol Hepatol Date: 2020-08-05 Impact factor: 13.576